GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Heartware International, Inc. (FRA:HIY1) » Definitions » EBITDA per Share

Heartware International, (FRA:HIY1) EBITDA per Share : €-0.06 (TTM As of Jun. 2016)


View and export this data going back to . Start your Free Trial

What is Heartware International, EBITDA per Share?

Heartware International,'s EBITDA per Share for the three months ended in Jun. 2016 was €-0.01. Its EBITDA per Share for the trailing twelve months (TTM) ended in Jun. 2016 was €-0.06.

During the past 3 years, the average EBITDA per Share Growth Rate was -17.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Heartware International,'s EBITDA per Share or its related term are showing as below:

FRA:HIY1' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -17.4   Med: -7.75   Max: 35.4
Current: -17.4

During the past 10 years, the highest 3-Year average EBITDA per Share Growth Rate of Heartware International, was 35.40% per year. The lowest was -17.40% per year. And the median was -7.75% per year.

FRA:HIY1's 3-Year EBITDA Growth Rate is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 7.7 vs FRA:HIY1: -17.40

Heartware International,'s EBITDA for the three months ended in Jun. 2016 was €-4.3 Mil.

During the past 3 years, the average EBITDA Growth Rate was -11.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 10 years, the highest 3-Year average EBITDA Growth Rate of Heartware International, was 53.80% per year. The lowest was -11.90% per year. And the median was 10.80% per year.


Heartware International, EBITDA per Share Historical Data

The historical data trend for Heartware International,'s EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heartware International, EBITDA per Share Chart

Heartware International, Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.07 -0.11 -0.06 - -0.09

Heartware International, Quarterly Data
Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.04 0.01 -0.02 -0.01

Heartware International, EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Heartware International,'s EBITDA per Share for the fiscal year that ended in Dec. 2015 is calculated as

EBITDA per Share(A: Dec. 2015 )
=EBITDA/Shares Outstanding (Diluted Average)
=-44.721/498.322
=-0.09

Heartware International,'s EBITDA per Share for the quarter that ended in Jun. 2016 is calculated as

EBITDA per Share(Q: Jun. 2016 )
=EBITDA/Shares Outstanding (Diluted Average)
=-4.301/572.378
=-0.01

EBITDA per Share for the trailing twelve months (TTM) ended in Jun. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Heartware International,  (FRA:HIY1) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Heartware International, EBITDA per Share Related Terms

Thank you for viewing the detailed overview of Heartware International,'s EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Heartware International, (FRA:HIY1) Business Description

Traded in Other Exchanges
N/A
Address
Heartware International Inc was incorporated in Delaware on July 29, 2008 and became the successor issuer to HeartWare Limited, an Australian corporation, on November 13, 2008, as a result of the Australian Court approved redomiciliation of HeartWare Limited from Australia to Delaware. HeartWare is a medical device company engaged in developing implantable blood pumps for the treatment of advanced heart failure. The Company operates one reportable segment which includes the design, manufacture and marketing of medical devices for the treatment of advanced heart failure. The HeartWare Ventricular Assist System, which includes a left ventricular assist device, or blood pump, patient accessories and surgical tools, is designed to provide circulatory support for patients with advanced heart failure. Beyond the HeartWare System, the company is also evaluating its next device, the Miniaturized Ventricular Assist Device. The MVAD is based on the same technology platform as the HeartWare System but adopts an axial flow, rather than a centrifugal flow, configuration and is being developed in multiple configurations. The MVAD designs are currently at the preclinical stage and undergoing animal studies focused on minimally invasive implantation techniques and are each approximately one-third the size of the HVAD Pump. The Company's competitors in the implantable cardiac assist space include Thoratec Corporation, Jarvik Heart, Inc., MicroMed Cardiovascular, Berlin Heart GmbH, and Sunshine Heart, Inc. HEARTWARE, HVAD, MVAD, PAL, CIRCULITE, SYNERGY and various company logos are the trademarks of the Company, in the United States, Europe, Australia and other countries.

Heartware International, (FRA:HIY1) Headlines

No Headlines